These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 31949479)

  • 21. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
    Kim YB; Ahn JM; Bae WJ; Sung CO; Lee D
    Int J Cancer; 2019 Aug; 145(4):916-926. PubMed ID: 30664822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma.
    Stenzel PJ; Schindeldecker M; Tagscherer KE; Foersch S; Herpel E; Hohenfellner M; Hatiboglu G; Alt J; Thomas C; Haferkamp A; Roth W; Macher-Goeppinger S
    Transl Oncol; 2020 Feb; 13(2):336-345. PubMed ID: 31881506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ARID1A gene mutation in ovarian and endometrial cancers (Review).
    Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
    Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of
    Kurzrock R; Aggarwal C; Weipert C; Kiedrowski L; Riess J; Lenz HJ; Gandara D
    Cancers (Basel); 2022 Sep; 14(17):. PubMed ID: 36077815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
    Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
    Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer.
    Yamashita H; Nakayama K; Ishikawa M; Nakamura K; Ishibashi T; Sanuki K; Ono R; Sasamori H; Minamoto T; Iida K; Sultana R; Ishikawa N; Kyo S
    Oncotarget; 2018 Jan; 9(5):5652-5664. PubMed ID: 29464025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical utility of tumor mutational burden in non-small cell lung cancer.
    Greillier L; Tomasini P; Barlesi F
    Transl Lung Cancer Res; 2018 Dec; 7(6):639-646. PubMed ID: 30505708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
    Hofman P; Heeke S; Alix-Panabières C; Pantel K
    Ann Oncol; 2019 Sep; 30(9):1448-1459. PubMed ID: 31228184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Identification of Immunological Biomarkers in Kidney Cancers.
    Lopez-Beltran A; Henriques V; Cimadamore A; Santoni M; Cheng L; Gevaert T; Blanca A; Massari F; Scarpelli M; Montironi R
    Front Oncol; 2018; 8():456. PubMed ID: 30450335
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
    Khalique S; Naidoo K; Attygalle AD; Kriplani D; Daley F; Lowe A; Campbell J; Jones T; Hubank M; Fenwick K; Matthews N; Rust AG; Lord CJ; Banerjee S; Natrajan R
    J Pathol Clin Res; 2018 Jul; 4(3):154-166. PubMed ID: 29659191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
    Davis AA; Patel VG
    J Immunother Cancer; 2019 Oct; 7(1):278. PubMed ID: 31655605
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors.
    Liu Y; Chen L; Zhang S; Shu Y; Qi Q; Zhu M; Peng Y; Ling Y
    Oncol Lett; 2020 Oct; 20(4):27. PubMed ID: 32774500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
    Damotte D; Warren S; Arrondeau J; Boudou-Rouquette P; Mansuet-Lupo A; Biton J; Ouakrim H; Alifano M; Gervais C; Bellesoeur A; Kramkimel N; Tlemsani C; Burroni B; Duche A; Letourneur F; Si H; Halpin R; Creasy T; Herbst R; Ren X; Morel P; Cesano A; Goldwasser F; Leroy K
    J Transl Med; 2019 Nov; 17(1):357. PubMed ID: 31684954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
    Stühler V; Maas JM; Bochem J; da Costa IA; Todenhöfer T; Stenzl A; Bedke J
    World J Urol; 2019 Sep; 37(9):1773-1784. PubMed ID: 30374610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.